PURPOSE: The association of depression and increased mortality in the general population, and also various medical conditions, is well documented. However, depression is not well studied in the setting of hematopoietic stem-cell transplantation (HSCT). We examined the association between depressive syndrome and survival after HSCT. PATIENTS AND METHODS: A total of 193 patients who received autologous or allogeneic HSCT from Brigham and Women's Hospital or Dana-Farber Cancer Institute were evaluated prospectively. The self-rated Likert-scaled symptom checklist, the SF-36, and the Spitzer Quality of Life Index Scale were administered. Outcomes evaluated included survival and quality of life. RESULTS: Sixty-seven patients (35%) satisfied the criteria for depressive syndrome. The 1-year probability of survival for the depressed and nondepressed patients was 85% (95% confidence interval [CI], 74% to 92%) and 94% (95% CI, 89% to 97%), respectively (P =.04). In multivariable modeling, depressed patients have a three-fold greater risk of dying than nondepressed patients (95% CI, 1.07 to 8.30; P =.04) between 6 and 12 months after HSCT after adjusting for other prognostic factors. Global inferiority in quality of life was observed in the depressed cohort when last measured at 24 months after transplantation. CONCLUSION: Depressive syndrome after HSCT is associated with decreased survival, at least from 6 to 12 months after transplantation. Persistence of this association after controlling for possible confounding factors suggests that depression may be more than simply a marker for concurrent ill health. This study raises an interesting hypothesis as to whether psychological or pharmacologic intervention for depression after HSCT can improve survival and/or quality of life.
PURPOSE: The association of depression and increased mortality in the general population, and also various medical conditions, is well documented. However, depression is not well studied in the setting of hematopoietic stem-cell transplantation (HSCT). We examined the association between depressive syndrome and survival after HSCT. PATIENTS AND METHODS: A total of 193 patients who received autologous or allogeneic HSCT from Brigham and Women's Hospital or Dana-Farber Cancer Institute were evaluated prospectively. The self-rated Likert-scaled symptom checklist, the SF-36, and the Spitzer Quality of Life Index Scale were administered. Outcomes evaluated included survival and quality of life. RESULTS: Sixty-seven patients (35%) satisfied the criteria for depressive syndrome. The 1-year probability of survival for the depressed and nondepressed patients was 85% (95% confidence interval [CI], 74% to 92%) and 94% (95% CI, 89% to 97%), respectively (P =.04). In multivariable modeling, depressedpatients have a three-fold greater risk of dying than nondepressed patients (95% CI, 1.07 to 8.30; P =.04) between 6 and 12 months after HSCT after adjusting for other prognostic factors. Global inferiority in quality of life was observed in the depressed cohort when last measured at 24 months after transplantation. CONCLUSION:Depressive syndrome after HSCT is associated with decreased survival, at least from 6 to 12 months after transplantation. Persistence of this association after controlling for possible confounding factors suggests that depression may be more than simply a marker for concurrent ill health. This study raises an interesting hypothesis as to whether psychological or pharmacologic intervention for depression after HSCT can improve survival and/or quality of life.
Authors: Anna Barata; Brian D Gonzalez; Steven K Sutton; Brent J Small; Paul B Jacobsen; Teresa Field; Hugo Fernandez; Heather Sl Jim Journal: J Health Psychol Date: 2016-04-22
Authors: Areej El-Jawahri; Yi-Bin Chen; Ruta Brazauskas; Naya He; Stephanie J Lee; Jennifer M Knight; Navneet Majhail; David Buchbinder; Raquel M Schears; Baldeep M Wirk; William A Wood; Ibrahim Ahmed; Mahmoud Aljurf; Jeff Szer; Sara M Beattie; Minoo Battiwalla; Christopher Dandoy; Miguel-Angel Diaz; Anita D'Souza; Cesar O Freytes; James Gajewski; Usama Gergis; Shahrukh K Hashmi; Ann Jakubowski; Rammurti T Kamble; Tamila Kindwall-Keller; Hilard M Lazarus; Adriana K Malone; David I Marks; Kenneth Meehan; Bipin N Savani; Richard F Olsson; David Rizzieri; Amir Steinberg; Dawn Speckhart; David Szwajcer; Helene Schoemans; Sachiko Seo; Celalettin Ustun; Yoshiko Atsuta; Jignesh Dalal; Carmem Sales-Bonfim; Nandita Khera; Theresa Hahn; Wael Saber Journal: Cancer Date: 2017-01-19 Impact factor: 6.860
Authors: Ludovic Belle; Vivian Zhou; Kara L Stuhr; Margaret Beatka; Emily M Siebers; Jennifer M Knight; Michael W Lawlor; Casey Weaver; Misato Hashizume; Cecilia J Hillard; William R Drobyski Journal: JCI Insight Date: 2017-07-20
Authors: Sheri L Robb; Debra S Burns; Kristin A Stegenga; Paul R Haut; Patrick O Monahan; Jane Meza; Timothy E Stump; Brooke O Cherven; Sharron L Docherty; Verna L Hendricks-Ferguson; Eileen K Kintner; Ann E Haight; Donna A Wall; Joan E Haase Journal: Cancer Date: 2014-01-27 Impact factor: 6.860
Authors: Jennifer M Knight; Karen L Syrjala; Navneet S Majhail; Michael Martens; Jennifer Le-Rademacher; Brent R Logan; Stephanie J Lee; Paul B Jacobsen; William A Wood; Heather S L Jim; John R Wingard; Mary M Horowitz; Muneer H Abidi; Mingwei Fei; Laura Rawls; J Douglas Rizzo Journal: Biol Blood Marrow Transplant Date: 2016-08-23 Impact factor: 5.742